VASOGENIC EDEMA AND HYDROCEPHALUS AS COMPLICATIONS OF GLIOBLASTOMA
Main Article Content
Ari Bandana Tasrif
Glioblastoma is the most aggressive and common primary brain tumor in adults, characterized by rapid growth, infiltrative behavior, and poor prognosis despite multimodal treatment. Among its most significant complications are vasogenic edema and hydrocephalus, which exacerbate intracranial hypertension and contribute substantially to morbidity and mortality. We report the case of a 59-year-old male who presented with progressive decreased consciousness, severe headaches, right-sided weakness, and visual disturbances. Neuroimaging revealed a left temporoparietal mass with cystic, solid, and necrotic components, accompanied by extensive vasogenic edema, midline shift, and obstructive hydrocephalus. Histopathological examination confirmed glioblastoma, WHO grade IV. The patient was treated with intravenous dexamethasone and acetazolamide, resulting in improved consciousness and partial symptomatic relief. This case illustrates the pathophysiological role of blood–brain barrier disruption in vasogenic edema and cerebrospinal fluid flow obstruction in hydrocephalus. Dexamethasone remains the cornerstone of symptomatic management for edema, while acetazolamide may provide temporary benefit in hydrocephalus, although its long-term efficacy is limited. The coexistence of these complications significantly worsens prognosis, and treatment primarily focuses on symptom control and quality of life. Prompt recognition and appropriate management are essential to stabilize patients, even though overall survival in glioblastoma remains limited.
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231–1251.
Li C, Li B, Wang H, Qu L, Liu H, Weng C, Han J, Li Y. Role of N6-methyladenosine methylation in glioma: recent insights and future directions. Cell Mol Biol Lett. 2023 Dec 11;28(1):103.
Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, Villano JL. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1985-96.
Jiang C, Mogilevsky C, Belal Z, Kurtz G, Alonso-Basanta M. Hypofractionation in Glioblastoma: An Overview of Palliative, Definitive, and Exploratory Uses. Cancers (Basel). 2023 Nov 29;15(23)
Ohmura, K.; Tomita, H.; Hara, A. Peritumoral Edema in Gliomas: A Review of Mechanisms and Management. Biomedicines 2023, 11, 2731. https://doi.org/10.3390/biomedicines11102731
Alfayate, RP.; Camarero, SC.; Montoya, JP.; Saenz, AA.; Granada,AC.; Lera, PA.; Grasso, G. Communicating hydrocephalus in glioblastoma presenting as chronic hydrocephalus: systematic review and meta-analysis. Acta Neurochirurgica (2025) 167:19. https://doi.org/10.1007/s00701-024-06414-2
Scheffler, P.; Fung, C.; Momjian, S.; Koessinger, D.; Häni, L.; Neidert, N.; Straehle, J.; Volz, F.; Schnell, O.; Beck, J.; et al. Dexamethasone in Patients with Glioblastoma: A Systematic Review and Meta-Analysis. Cancers 2024, 16, 1393. https://doi.org/10.3390/cancers16071393
Del Bigio, MR & Di Curzio, DL. Nonsurgical therapy for hydrocephalus: a comprehensive and critical review. Fluids Barriers CNS (2016) 13:3. DOI 10.1186/s12987-016-0025-2
Shahrabi M, Abdollahi A, Lahiji MN et al. Effects of steroids on vasogenic edema due to brain tumors, a narrative review. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management 41 (2025) 102106. https://doi.org/10.1016/j.inat.2025.102106
Alperin N et al. Low-dose acetazolamide reverses periventricular white matter hyperintensities in iNPH. Neurology 2014 Mar 14; (http://dx.doi.org/10.1212/WNL.0000000000000313)
Barbuskaite D, Oernbo EK, Wardman JH et al. Acetazolamide modulates intracranial pressure directly by its action on the cerebrospinal fluid secretion apparatus. Fluids and Barriers of the CNS (2022) 19:53. https://doi.org/10.1186/s12987-022-00348-6
